Agilent to Split into Two Companies; Life Sciences, Dx Business to Combine | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies announced today that it will split into two publicly-traded companies — one focused on its life science and diagnostics business and the other on its electronic measurement business.

The life sciences and diagnostics business, which also includes applied markets, has annual revenues of around $3.9 billion. It will retain the Agilent name, and current Agilent CEO William Sullivan will retain the same role and also serve as president of the company. CFO Didier Hirsch also will continue as CFO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.